UNSPSC 51351900: Estrogen, progestin, or internal contraceptive norpregnanes

Estrogens, progestins, or internal contraceptives made from pregnanes which have undergone ring contractions or are lacking carbon-18 or carbon-19.

UNSPSC 51351900 Estrogen, progestin, or internal contraceptive norpregnanes, a Class code, describes contraceptive pharmaceutical products that state and local government health systems procure through cooperative purchasing agreements. The code encompasses oral contraceptives, intrauterine devices, implants, and related hormonal and barrier contraceptive products supplied to public health departments, Medicaid programs, correctional facilities, and municipal health clinics. State and local buyers source these items primarily through multi-state cooperative purchasing vehicles and established wholesaler networks rather than direct vendor engagement, which concentrates procurement activity around a small number of high-volume cooperative agreements that serve multiple jurisdictions simultaneously. The mix of issuing bodies includes state health departments, state Medicaid offices, and county public health systems, though purchasing typically flows through cooperative alliances that aggregate demand across dozens of member agencies to achieve volume pricing and streamlined distribution.

Recent activity centers on the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, which issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline. The solicitation (S1070000015802) spans participating state and local government facilities in Minnesota and Oregon, requiring vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded contracts effective July 1, 2026. Evaluation emphasizes price competitiveness at 75 percent of the award decision, with secondary weight on fixed pricing, EDI capability, administrative fee compliance, and format adherence. Vendors must maintain $5,000,000 commercial general liability coverage and demonstrate cGMP and DSCSA compliance; no set-aside restrictions are noted in the available documentation.